日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers

针对唾液腺癌的定制化组织学驱动分子谱分析算法方案

Alfieri, S; Rota, S; Romanò, R; Capone, I; Busico, A; Conca, E; Tamborini, E; Cavalieri, S; Buriolla, S; Sciortino, C; Leone, A G; Nuzzolese, I; Ottini, A; Bergamini, C; Quattrone, P; Vingiani, A; Locati, L D; Licitra, L; Pruneri, G; Colombo, E; Agnelli, L; Perrone, F

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模式肿瘤非特异性ctDNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

Paracchini, L; Velle, A; Di Gennaro, P; Mannarino, L; Ancona, L; Lorusso, D; Cecere, S C; Colombo, N; Beltrame, L; Fagotti, A; Tasca, G; Piemontese, M; Arenare, L; Califano, D; Galdiero, F; Zadro, R; Chiodini, P; Perrone, F; Biagioli, E; D'Incalci, M; Romualdi, C; Pignata, S; Marchini, S

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

HOBOE III期试验十年更新结果,比较曲普瑞林联合他莫昔芬或来曲唑,或唑来膦酸联合来曲唑治疗绝经前激素受体阳性早期乳腺癌患者

Gravina, A; Gargiulo, P; De Laurentiis, M; Arenare, L; De Placido, S; Orditura, M; Cinieri, S; Riccardi, F; Ribecco, A S; Putzu, C; Del Mastro, L; Rossi, E; Ciardiello, F; Di Rella, F; Nuzzo, F; Pacilio, C; Caputo, R; Cianniello, D; Forestieri, V; Giuliano, M; Arpino, G; Orlando, L; Mocerino, C; Schettino, C; Piccirillo, M C; Gallo, C; Perrone, F

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib

HR-SC 是一个学术界开发的机器学习框架,用于对 HRD 阳性卵巢癌患者进行分类并预测其对奥拉帕尼的敏感性。

Beltrame, L; Mannarino, L; Sergi, A; Velle, A; Treilleux, I; Pignata, S; Paracchini, L; Harter, P; Scambia, G; Perrone, F; González-Martin, A; Berger, R; Arenare, L; Hietanen, S; Califano, D; Derio, S; Van Gorp, T; Dalessandro, M L; Fujiwara, K; Provansal, M; Lorusso, D; Buderath, P; Masseroli, M; Ray-Coquard, I; Pujade-Lauraine, E; Romualdi, C; D'Incalci, M; Marchini, S

Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)

评估癌症患者药物相互作用的临床相关性和方法学方法:意大利肿瘤内科学会 (AIOM) 和意大利药理学会 (SIF) 的立场声明

Del Re, M; Roncato, R; Argentiero, A; Berrino, L; Botticelli, A; Capuano, A; Di Donato, S; Fogli, S; Marino, D; Rodriquenz, G; Speranza, D; Perrone, F; Silvestris, N; Danesi, R

Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)

癌症治疗中的性健康:意大利肿瘤内科学会 (AIOM) 的叙述性综述和立场声明

Rossi, A; Leone, A G; Lambertini, M; Sperti, E; Cassani, C; Vetromile, A; Barni, S; De Giorgi, A; Preti, E P; Secondino, S; Silvestris, N; Berardi, R; Brunello, A; Curigliano, G; La Verde, N; Latiano, T P; Pietrantonio, F; Tiseo, M; Di Maio, M; Perrone, F; Cinieri, S; Fabi, A

Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study

分子检测和精准肿瘤学对转诊中心晚期甲状腺癌患者的影响:OrienTHYring真实世界研究

Colombo, E; Cavalieri, S; Vingiani, A; Agnelli, L; Duca, M; Paolini, B; Perrone, F; Tamborini, E; Capone, I; Piccolo, A; Caspani, F; Bergamini, C; Alfieri, S; Resteghini, C; Nuzzolese, I; Ottini, A; Buriolla, S; Salvetti, M; Calareso, G; Milione, M; Pruneri, G; Locati, L D; Licitra, L

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期胃肠胰神经内分泌肿瘤管理临床实践指南:采用 GRADE 方法进行证据评估和建议,由意大利肿瘤内科学会 (AIOM) 与意大利神经内分泌肿瘤协会 (ITANET) 合作制定。

Spada, F; Gelsomino, F; Rinzivillo, M; Cinquini, M; Fittipaldo, V A; Tralongo, A; Moschetti, I; Albertelli, M; Ambrosini, V; Amoroso, V; Antonuzzo, L; Badalamenti, G; Bajetta, E; Baldari, S; Barberis, M; Berruti, A; Bertani, E; Bonomo, G; Bodei, L; Buzzoni, R; Brizzi, M P; Campana, D; Capurso, G; Casadei, R; Castellano, M; Cingarlini, S; Cives, M; Colao, A M; Coppa, J; Cremonini, N; Davì, M V; De Angelis, C G; de Braud, F; De Robertis, R; Faggiano, A; Falconi, M; Fassan, M; Ferolla, P; Ferone, D; Filice, A; Fiore, F; Funicelli, L; Granata, V; Giuffrida, D; Grana, C M; Grimaldi, F; Ibrahim, T; La Salvia, A; Laghi, A; Luppi, G; Maccauro, M; Marconcini, R; Massironi, S; Mazzaferro, V; Merola, E; Milione, M; Modica, R; Ortolani, S; Papotti, M G; Partelli, S; Pelosi, G; Pusceddu, S; Ramundo, V; Ravizza, D; Razzore, P; Reimondo, G; Ricci, C; Rindi, G; Rizzo, F M; Rossi, R E; Tafuto, S; Tiberio, G A M; Versari, A; Vigorito, R; Zatelli, M C; Di Maio, M; Perrone, F; Cinieri, S; Panzuto, F; Fazio, N

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

晚期子宫内膜癌同源重组修复状态:来自随机 II 期 MITOEND 3 试验的探索性生物标志物分析

Bartoletti, M; Passarelli, A; Fagotti, A; Andreetta, C; Tamberi, S; Lorusso, D; Pisano, C; Califano, D; Spina, A; De Angelis, C; Greco, F; De Cecio, R; Scaglione, G L; Russo, D; Ghizzoni, V; Cinieri, S; Sisoudiya, S D; Sokol, E S; Arenare, L; Schettino, C; Perrone, F; Farolfi, A; Pignata, S

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

外周单核细胞髓系衍生抑制细胞与接受卡铂+紫杉醇/avelumab治疗的单中心子宫内膜癌患者的分子亚型的关联(MITO-END3试验)

D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, Azzaro R, Mignogna C, Scognamiglio G, Califano D, Arenare L, Schettino C, Pisano C, Cecere S C, Di Napoli M, Passarelli A, Perrone F, Pignata S, Scala S